查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012495

臍帶血庫市場：按庫型、服務、應用和最終用戶分類－2026-2032年全球預測

Umbilical Cord Blood Banking Market by Banking Model, Offerings, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，臍帶血庫市場價值將達到 385.2 億美元，到 2026 年將成長至 448.6 億美元，到 2032 年將達到 1,194.4 億美元，年複合成長率為 17.54%。

主要市場統計數據
基準年 2025 385.2億美元
預計年份：2026年 448.6億美元
預測年份 2032 1194.4億美元
複合年成長率 (%) 17.54%

說明整體情況了不斷發展的臍帶血庫產業，重點在於影響策略決策的臨床期望、營運挑戰和監管趨勢。

臍帶血庫領域正處於臨床需求、技術創新和不斷變化的監管要求的交匯點。細胞處理和冷凍保存技術的進步重新激發了臨床醫生、研究人員和準父母的興趣，而不斷擴展的治療應用也促進了產業與監管機構之間更深入的對話。因此，相關人員如今正面臨一個生物資產長期儲存與短期轉化科學結合的複雜環境。

科學進步、營運標準化和不斷發展的臨床夥伴關係如何重塑整個產業的競爭重點和品質期望。

臍帶血庫產業正經歷一場變革，這場變革的驅動力來自科學進步、處理技術的改進以及相關人員期望的不斷變化。再生醫學和細胞療法的突破性進展正在拓展臍帶血保存的臨床意義，促使現有臍帶血庫和新參與企業重新評估其服務模式和價值提案。同時，自動化和標準化的活力檢測提高了醫療專業人員和研究人員對品質標準的期望，並將競爭的焦點從價格轉向了已證實的臨床效用。

評估 2025 年貿易政策調整和關稅如何重塑該產業的採購、供應鏈韌性和聯合研究策略。

美國2025年實施的貿易政策措施和關稅調整，給在全球臍帶血庫供應鏈中運作的組織帶來了新的營運和戰略壓力。雖然採購專用低溫冷凍庫、實驗室耗材和試劑通常依賴跨境供應商，但關稅導致的投入成本增加迫使企業即時重新評估籌資策略。為此，許多相關人員加快了供應商多元化進程，並活性化討論將關鍵製造能力外包到近岸地區的問題。

詳細的細分分析揭示了每種銀行模式、服務產品、臨床應用和最終用戶期望的不同需求，從而推動了策略差異化。

從銀行模式的角度評估市場時，可以明顯看出兩類供應商的差異：一類專注於個人化儲存服務，另一類則面向大眾使用和器官移植支援。私人銀行傾向於投資消費者意識宣傳活動、長期客戶維繫以及與家庭主導的獲取途徑相關的價值提案，而公共銀行則優先考慮捐贈者招募、匹配系統以及與國家移植網路的合作。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢和監管細微差別決定了投資重點和戰略夥伴關係。

區域趨勢對法律規範、支付方態度以及臍帶血庫生態系的成熟度有顯著影響。在美洲，成熟的私人臍帶血庫網路與公共登記系統並存，臨床中心擁有良好的移植記錄，從而支撐了對高品質臍帶血的持續需求。區域監管機構正在逐步更新指導方針以應對細胞療法，而私人企業則傾向於專注於消費者互動和產品差異化。

對競爭格局的評估表明，合作夥伴關係、技術差異化和產業重組正在重新定義企業策略和價值創造路徑。

臍帶血庫產業的競爭格局由傳統儲存服務商、垂直整合的臨床服務機構以及將創新處理和分析技術商業化的敏捷型Start-Ups組成。成熟的儲存服務商通常利用其採集網路、客戶關係和規模經濟優勢來進行長期儲存業務，而新參與企業則傾向於專注於差異化的偵測能力、專有的活力檢測方法或與藥物研發公司的合作。

為領導者制定可操作的策略重點，重點在於產生臨床證據、業務永續營運、策略夥伴關係和客戶參與，以確保長期價值。

產業領導者應優先考慮平衡策略，既確保業務永續營運，也要提升臨床可信度。首先，他們需要透過前瞻性註冊研究和與臨床醫生合作，投資於實證醫學證據的收集，以驗證效用。這些工作應與完善的品質系統和透明的文件記錄相協調，以促進與監管機構的溝通，並支援與支付方的對話。

一個強大的混合研究框架，結合專家訪談、監管審查和資料檢驗，為基於證據的策略建議提供支援。

本研究整合了對關鍵相關人員的訪談、監管和臨床文獻的回顧以及對工作實踐的觀察分析，以得出循證結論。關鍵要素包括與實驗室主任、移植臨床醫生、器官捐贈協調員和監管事務專家進行結構化對話，以了解實際挑戰和不斷變化的期望。除了這些訪談外，研究還仔細審查記錄程序創新和治療結果的指導文件、臨床試驗註冊資訊以及同行評審的研究。

本報告總結了品質、策略夥伴關係和供應鏈韌性如何決定哪些組織主導下一階段的治療和臨床部署的結論。

科學進步、運作標準化和地緣政治壓力相互交織，正為臍帶血庫生態系統帶來意義深遠的改變。目前，除了臨床應用機會外，人們對臍帶血庫的可追溯性、品質和協作證據產生也提出了更高的期望。同時，供應鏈中斷和關稅趨勢凸顯了採購彈性和區域能力建構的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：臍帶血庫市場：依血庫模式分類

  • 私人的
  • 民眾

第9章：臍帶血庫市場：依供應方式

  • 收藏
  • 過程
    • 細胞分離
    • 存活率檢驗
    • 產能下降
  • 發布
  • 保持

第10章：臍帶血庫市場：依應用領域分類

  • 血液疾病
    • 貧血
    • 白血病
    • 淋巴瘤
  • 免疫疾病
  • 代謝性疾病
  • 再生醫學
  • 調查

第11章：臍帶血庫市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院和診所
  • 研究機構

第12章 臍帶血庫市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：臍帶血庫市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 臍帶血庫市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：臍帶血庫市場

第16章 中國：臍帶血庫市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cell Care Pty Ltd
  • Cord Blood Registry, LLC
  • Cryo-Cell International, Inc.
  • LifeCell International Private Limited
  • Macopharma SA
  • Smart Cells International
  • StemCyte, Inc.
  • Stemlife Berhad
  • ViaCord
  • ViaCord, LLC
Product Code: MRR-430D5F382283

The Umbilical Cord Blood Banking Market was valued at USD 38.52 billion in 2025 and is projected to grow to USD 44.86 billion in 2026, with a CAGR of 17.54%, reaching USD 119.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 38.52 billion
Estimated Year [2026] USD 44.86 billion
Forecast Year [2032] USD 119.44 billion
CAGR (%) 17.54%

Comprehensive orientation to the evolving cord blood banking landscape highlighting clinical promise, operational imperatives, and regulatory dynamics shaping strategic decisions

The umbilical cord blood banking field stands at the intersection of clinical promise, technological innovation, and evolving regulatory expectations. Advances in cell processing and cryopreservation have catalyzed renewed interest among clinicians, researchers, and prospective parents, while expanding therapeutic applications are driving deeper conversations between industry and regulators. As a result, stakeholders now navigate a landscape that blends long-term custody of biological assets with near-term translational science.

In practice, banking models and service offerings reflect distinct value propositions. Private banks emphasize individualized storage for potential autologous or family-directed use, while public banks focus on allogeneic availability for transplantation and research. Concurrently, improvements in laboratory automation, quality control, and viability assessment have compressed operational variances, enabling higher consistency across providers. Regulatory frameworks continue to shape permissible activities and commercialization pathways, and organizations that align clinical evidence generation with robust quality systems gain differentiated credibility.

This introduction frames the core dynamics that follow: structural shifts across the ecosystem, policy pressures from trade measures, segmentation-specific drivers, and practical recommendations for leaders who must translate scientific opportunity into reliable, compliant services. Through this lens, the remainder of the document outlines the forces that will most influence strategic choices over the near to medium term.

How scientific advances, operational standardization, and evolving clinical partnerships are reshaping competitive priorities and quality expectations across the industry

The landscape of cord blood banking is undergoing transformative shifts driven by converging scientific advances, improvements in processing technologies, and changing stakeholder expectations. Breakthroughs in regenerative medicine and cell therapy have expanded the clinical rationale for preserving cord blood, prompting both established banks and new entrants to revisit service models and value communications. At the same time, automation and standardized viability testing have raised the baseline quality that caregivers and researchers now expect, shifting competition away from price toward demonstrated clinical utility.

Moreover, partnerships between banking organizations and biotechnology firms are accelerating translational pathways. These collaborations foster shared investment in protocols that support novel applications, including immunotherapies and regenerative indications. Concurrently, payers and health systems are beginning to evaluate long-term outcomes, which will influence reimbursement conversations and patient demand. Regulatory bodies are also adapting oversight frameworks to accommodate emerging cell-based therapies, creating new compliance requirements that necessitate proactive quality and documentation strategies.

Taken together, these factors are reshaping strategic priorities across the sector. Organizations that invest in evidence generation, strengthen traceability and cold chain governance, and cultivate clinical partnerships will navigate the transition more successfully, while those that delay integration of new technologies and regulatory alignment may face competitive and compliance risks.

Assessment of how 2025 trade policy adjustments and tariffs reshaped procurement, supply chain resilience, and collaborative research strategies within the sector

The introduction of trade policy measures and tariff adjustments by the United States in 2025 introduced a new set of operational and strategic pressures for organizations active in global supply chains supporting cord blood banking. Sourcing of specialized cryogenic freezers, laboratory consumables, and reagents often relies on cross-border suppliers, and tariff-driven input cost increases necessitated immediate reassessment of procurement strategies. In response, many stakeholders accelerated supplier diversification and intensified conversations about nearshoring of critical manufacturing capacity.

Beyond procurement, tariffs influenced collaborative research arrangements. Cross-border clinical collaborations and reagent sharing require clear contractual terms to manage cost volatility. Institutions adapted by revising contractual risk allocations and by establishing inventory buffers for time-sensitive reagents. Additionally, the heightened cost visibility prompted innovation in resource utilization, such as optimizing storage formats and improving volume reduction techniques to reduce consumable consumption per specimen.

From a strategic perspective, the tariff environment catalyzed stronger emphasis on supply chain transparency and resilience. Organizations that had previously underinvested in supplier qualification and contingency planning found themselves revisiting those priorities. Conversely, those that leveraged strategic procurement, long-term supplier agreements, and incremental investments in domestic capabilities minimized disruption and maintained continuity of clinical and research activities.

Deep segmentation analysis revealing distinct requirements across banking models, service offerings, clinical applications, and end-user expectations that drive strategic differentiation

When evaluating the market through the lens of banking model, a clear dichotomy emerges between providers focused on individualized custodial services and those oriented toward public availability and transplantation support. Private banks tend to invest in consumer-facing education, long-term customer retention, and value propositions tied to family-directed access, while public banks prioritize donor recruitment, matching systems, and integration with national transplant networks.

Examining offerings reveals discrete operational domains: collection processes that ensure sterile, timely retrieval at birth; processing functions that include cell separation, viability testing, and volume reduction to prepare units for cryostorage; release procedures that govern clinical dispatch for transplantation or research; and long-term storage systems that maintain sample integrity under rigorous traceability and temperature control. Innovations in any of these stages can materially affect downstream usability and cost structures.

Application-based segmentation highlights clinical and scientific priorities. Blood disorders such as anemia, leukemia, and lymphoma remain core therapeutic targets for cord blood transplantation, while immune disorders and metabolic conditions continue to drive research interest. Regenerative medicine and research applications expand the potential utility of stored units, requiring additional data on potency and longer-term outcomes to support wider adoption.

Finally, end users-including diagnostic laboratories, hospitals and clinics, and research institutes-engage with banks under different time horizons and quality expectations. Diagnostic laboratories often require validated sample processing and strict chain-of-custody documentation, whereas hospitals and clinics demand operational excellence at the point of collection and seamless clinical integration. Research institutes prioritize accessibility and standardized metadata to enable reproducible studies. Understanding these nuanced needs across segmentation axes informs tailored service design and contract structures.

Regional dynamics and regulatory nuances across the Americas, Europe-Middle East-Africa, and Asia-Pacific that determine investment priorities and strategic partnerships

Regional dynamics exert powerful influence on regulatory frameworks, payer attitudes, and the maturity of cord blood banking ecosystems. In the Americas, established private banking networks coexist with public registries, and clinical centers maintain strong transplantation experience that supports sustained demand for high-quality units. Regional regulatory bodies have incrementally updated guidance to accommodate cell therapies, and commercial players often emphasize consumer engagement and product differentiation.

In Europe, the Middle East & Africa region, regulatory harmonization efforts and national tissue directives shape operational requirements. Public banking infrastructure and national registries play a prominent role in certain countries, while cross-border cooperation supports transplantation matching. Regulatory nuance across jurisdictions requires banks to invest in multi-jurisdictional compliance programs and localized clinical partnerships to ensure access to varied patient populations.

Across the Asia-Pacific region, rapid adoption of novel therapies and investment in biotechnology infrastructure drive demand for both private and public banking services. Growth in clinical trials and translational research has created opportunities for collaborative models between banks and therapeutic developers. However, heterogeneity in regulatory maturity and varying reimbursement landscapes necessitate localized strategies that account for cultural, clinical, and policy differences. These regional distinctions inform where to prioritize investments in infrastructure, clinical outreach, and compliance capabilities.

Competitive landscape assessment showing how alliances, technological differentiation, and consolidation are redefining company strategies and value creation pathways

Competitive dynamics in the cord blood banking sector reflect a mix of legacy custodial providers, vertically integrated clinical service organizations, and nimble startups that commercialize novel processing and analytics technologies. Established custodial providers typically leverage scale in collection networks, customer relationships, and long-term storage operations, while newer entrants often focus on differentiated laboratory capabilities, proprietary viability assays, or partnerships with therapeutic developers.

Strategic alliances between banks and biotechnology companies have become increasingly prevalent as developers seek reliable, high-quality source material for clinical programs. These alliances frequently include co-investment in processing protocols, validation studies, and data sharing agreements that accelerate translational timelines. Similarly, technology vendors supplying automated processing platforms and advanced cryogenic hardware have created opportunities for banks to raise quality standards and reduce per-unit variability.

Mergers and acquisitions continue to influence the competitive landscape, with consolidation enabling scale economies in storage and compliance while also driving integration of clinical and research services. At the same time, institutional investors and healthcare systems are exploring joint ventures and captive banking solutions to secure access to qualified donor material for internal therapeutic pipelines. In aggregate, these company-level strategies reflect a market where differentiation increasingly rests on evidence generation, supply chain reliability, and the capacity to support clinical development partners.

Actionable strategic priorities for leaders focused on clinical evidence generation, operational resilience, strategic partnerships, and customer engagement to secure long-term value

Industry leaders should prioritize a balanced approach that strengthens clinical credibility while building operational resilience. First, invest in evidence generation through prospective registries and clinician partnerships to substantiate clinical utility across target indications. Align these efforts with robust quality systems and transparent documentation to ease regulatory interactions and support payer conversations.

Second, enhance supply chain resilience by diversifying vendors for critical equipment and consumables, negotiating multi-year agreements where feasible, and exploring regional manufacturing or procurement hubs to mitigate tariff-driven volatility. Simultaneously, adopt laboratory automation and standardized viability testing to reduce operational variability and improve unit usability for translational programs.

Third, pursue strategic collaborations with therapeutic developers and research institutes. Co-development agreements and material access arrangements can create new revenue streams and accelerate the clinical validation of cord blood-derived applications. Finally, strengthen customer-facing capabilities through clearer education, post-storage engagement, and digital portals that simplify long-term custody decisions and enable lifecycle monetization opportunities. Taken together, these actions will position organizations to capture clinical opportunities while managing regulatory and commercial risk.

Robust mixed-methods research framework combining expert interviews, regulatory review, and data triangulation to underpin evidence-based strategic recommendations

This research synthesizes primary stakeholder interviews, regulatory and clinical literature review, and observational analysis of operational practices to construct evidence-based conclusions. Primary engagement included structured conversations with laboratory directors, transplant clinicians, procurement specialists, and regulatory affairs professionals to capture practical challenges and evolving expectations. These interviews were complemented by careful review of guidance documents, clinical trial registries, and peer-reviewed studies that document procedural innovations and therapeutic outcomes.

Secondary research incorporated industry publications, technology vendor specifications, and publicly available policy updates to contextualize operational trends within broader trade and regulatory developments. Data triangulation ensured consistency across sources, with discrepant findings subjected to follow-up inquiries or cross-verification through alternate data channels. Quality assurance processes included expert peer review and scenario analysis to identify plausible responses to policy shifts and technological adoption curves.

Methodologically, the study emphasized qualitative depth over speculative quantitative projections. That emphasis enables readers to understand causal relationships, operational levers, and the pragmatic steps required to translate scientific promise into dependable services. Transparency in source attribution and methodological limitations accompanies all major assertions to support confident decision-making.

Conclusion summarizing how quality, strategic partnerships, and supply chain resilience determine which organizations will lead the next phase of therapeutic and clinical adoption

The convergence of scientific advances, operational standardization, and geopolitical pressures is reshaping the cord blood banking ecosystem in meaningful ways. Clinical opportunity now coexists with increased expectations for traceability, quality, and collaborative evidence generation. At the same time, supply chain disruptions and tariff dynamics have highlighted the importance of procurement agility and regional capacity building.

Organizations that align laboratory excellence with proactive regulatory engagement and strategic partnerships will secure competitive advantage. Investing in validated processing protocols, automated viability testing, and durable clinical relationships creates a foundation for long-term relevance. Conversely, those that delay integrating new technologies or fail to shore up supply chain resilience risk operational discontinuities and diminished clinical credibility.

In closing, the sector's trajectory favors actors who view cord blood banking not merely as a custodial service, but as an integral partner in translational science. By emphasizing quality, collaboration, and adaptability, leaders can unlock broader clinical applications while safeguarding the integrity of stored biological assets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Umbilical Cord Blood Banking Market, by Banking Model

  • 8.1. Private
  • 8.2. Public

9. Umbilical Cord Blood Banking Market, by Offerings

  • 9.1. Collection
  • 9.2. Processing
    • 9.2.1. Cell Separation
    • 9.2.2. Viability Testing
    • 9.2.3. Volume Reduction
  • 9.3. Release
  • 9.4. Storage

10. Umbilical Cord Blood Banking Market, by Application

  • 10.1. Blood Disorders
    • 10.1.1. Anemia
    • 10.1.2. Leukemia
    • 10.1.3. Lymphoma
  • 10.2. Immune Disorders
  • 10.3. Metabolic Disorders
  • 10.4. Regenerative Medicine
  • 10.5. Research

11. Umbilical Cord Blood Banking Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Umbilical Cord Blood Banking Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Umbilical Cord Blood Banking Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Umbilical Cord Blood Banking Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Umbilical Cord Blood Banking Market

16. China Umbilical Cord Blood Banking Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Cell Care Pty Ltd
  • 17.6. Cord Blood Registry, LLC
  • 17.7. Cryo-Cell International, Inc.
  • 17.8. LifeCell International Private Limited
  • 17.9. Macopharma S.A.
  • 17.10. Smart Cells International
  • 17.11. StemCyte, Inc.
  • 17.12. Stemlife Berhad
  • 17.13. ViaCord
  • 17.14. ViaCord, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 137. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 157. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 158. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 164. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 165. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)